• / Free eNewsletters & Magazine
  • / My Account
Home>PPD Strengthens Regulatory Consulting and Ophthalmology Expertise

PPD Strengthens Regulatory Consulting and Ophthalmology Expertise

PPD Strengthens Regulatory Consulting and Ophthalmology Expertise

10/03/2017

PPD Strengthens Regulatory Consulting and Ophthalmology Expertise

Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Jonca Bull, M.D., in a dual role as vice president of PPD® Consulting, where she will serve as the head of regulatory consulting and as vice president, ophthalmology, within global product development.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171003005963/en/

PPD has appointed Jonca Bull, M.D., to a dual role as vice president of PPD® Consulting and as vice ...

PPD has appointed Jonca Bull, M.D., to a dual role as vice president of PPD® Consulting and as vice president, ophthalmology, within global product development. (Photo: Business Wire)

Bull joined PPD from the U.S. Food and Drug Administration (FDA), where she most recently served as assistant commissioner and director of its Office of Minority Health.

“Jonca possesses a wealth of experience in the regulatory arena, including with the FDA and in the pharmaceutical industry,” said Rob Dow, chief medical officer for PPD. “Her experience working closely with pharmaceutical clients, as well as health and regulatory authorities, will help enhance patient engagement for PPD clients in developing life-changing therapies.”

PPD Consulting provides full drug development design and planning facilities, with broad experience of regulatory guidelines and the drug development process. Along with teams of consulting experts, the global product development teams coordinate multidisciplinary services and insight from therapeutic thought leaders to create customized development strategies to meet client needs.

In the past five years, PPD’s dedicated global ophthalmology team has facilitated more than 65 trials, which have involved more than 9,000 patients and 1,400 investigative sites. The team’s comprehensive services include drug development and consulting in all functional areas of expertise to assist PPD’s clients.

©2017 Morningstar Advisor. All right reserved.